International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 5 , Pages 1302-1308 , 1 August 2008

Body Mass Index and Prostate-Specific Antigen Failure Following Brachytherapy for Localized Prostate Cancer

  • Jason A. Efstathiou, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • Corresponding Author InformationReprint requests to: Jason A. Efstathiou, M.D., Ph.D., Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 3, Boston, MA 02114. Tel: (617) 724-1160; Fax: (617) 726-3603
    • ,
  • Rafi Y. Skowronski, M.S.

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • ,
  • John J. Coen, M.D.

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • ,
  • Joseph A. Grocela, M.D.

      Affiliations

    • Department of Urology, Massachusetts General Hospital, Boston, MA
    • ,
  • Ariel E. Hirsch, M.D.

      Affiliations

    • Department of Radiation Oncology, Boston Medical Center, Boston, MA
    • ,
  • Anthony L. Zietman, M.D.

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA

Received 5 June 2007 ,Revised 8 November 2007 ,Accepted 28 November 2007.

References 

  1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549–1555
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  3. Rapp K, Schroeder J, Klenk J, et al. Obesity and incidence of cancer: A large cohort study of over 145,000 adults in Austria. Br J Cancer. 2005;93:1062–1067
  4. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638
  5. Andersson SO, Wolk A, Bergstrom R, et al. Body size and prostate cancer: A 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst. 1997;89:385–389
  6. Giovannucci E, Rimm EB, Liu Y, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst. 2003;95:1240–1244
  7. Presti JC, Lee U, Brooks JD, et al. Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. J Urol. 2004;171:2199–2202
  8. Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate cancer: A follow-up of 950000 Norwegian men. Br J Cancer. 2003;89:1237–1242
  9. Schuurman AG, Goldbohm RA, Dorant E, et al. Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol. 2000;151:541–549
  10. Rodriguez C, Patel AV, Calle EE, et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev. 2001;10:345–353
  11. Snowdon DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol. 1984;120:244–250
  12. Siddiqui SA, Inman BA, Sengupta S, et al. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer. 2006;107:521–529
  13. Gong Z, Agalliu I, Lin DW, et al. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer. 2007;109:1192–1202
  14. Kane CJ, Bassett WW, Sadetsky N, et al. Obesity and prostate cancer clinical risk factors at presentation: Data from CaPSURE. J Urol. 2005;173:732–736
  15. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:439–445
  16. Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: A report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004;22:446–453
  17. Freedland SJ, Grubb KA, Yiu SK, et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol. 2005;174:919–922
  18. Strom SS, Wang X, Pettaway CA, et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res. 2005;11:6889–6894
  19. Strom SS, Kamat AM, Gruschkus SK, et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer. 2006;107:631–639
  20. Efstathiou JA, Chen MH, Renshaw AA, et al. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Cancer. 2007;109:1493–1498
  21. Grimm PD, Blasko JC, Sylvester JE, et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  22. Kollmeier MA, Stock RG, Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys. 2003;57:645–653
  23. Merrick GS, Butler WM, Wallner KE, et al. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer. W V Med J. 2005;101:168–171
  24. Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47:1261–1266
  25. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327–333
  26. Brachman DG, Thomas T, Hilbe J, et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys. 2000;48:111–117
  27. Potters L, Morgenstern C, Calugaru E, et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562–1566
  28. Blasko JC, Mate T, Sylvester JE, et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol. 2002;12:81–94
  29. Zelefsky MJ, Moughan J, Owen J, et al. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:1053–1061
  30. Merrick GS, Butler WM, Wallner KE, et al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology. 2005;65:95–100
  31. Beahrs OH, Henson DE, Hutter RVP. American Joint Committee on Cancer: Manual for staging cancer. 4th ed.. Philadelphia, PA: Lippincott; 1992;
  32. Wallner K, Merrick G, True L, et al. 125I versus 130Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys. 2003;57:1297–1303
  33. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys. 1995;22:209–234
  34. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—The evidence report. National Institutes of Health. Obes Res. 1998;(Suppl. 2):51S–209S
  35. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929–943
  36. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  37. Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45:553–561
  38. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  39. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
  40. Cox DR. Regression models and life tables. J R Stat Soc Series B. 1972;34:187–229
  41. Loeb S, Yu X, Nadler RB, et al. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?. J Urol. 2007;177:102–106discussion, 106
  42. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005;103:1092–1095
  43. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  44. Kuban DA, Levy LB, Potters L, et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:1487–1493
  45. Pasulka PS, Bistrian BR, Benotti PN, et al. The risks of surgery in obese patients. Ann Intern Med. 1986;104:540–546
  46. Song PY, Washington M, Vaida F, et al. A comparison of four patient immobilization devices in the treatment of prostate cancer patients with three dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1996;34:213–219
  47. Millender LE, Aubin M, Pouliot J, et al. Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:6–10
  48. Rockhill J, Wallner K, Hoffman C, et al. Prostate brachytherapy in obese patients. Brachytherapy. 2002;1:54–60
  49. Merrick GS, Butler WM, Wallner K, et al. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. Urology. 2002;60:104–108
  50. Blasko JC, Grimm PD, Sylsvester JE, et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol. 2000;57:273–278
  51. Merrick GS, Butler WM, Wallner KE, et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61:32–43
  52. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet. 2002;360:103–106
  53. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285–1290
  54. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6:841–850
  55. D'Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA. 2004;292:821–827
  56. Barry MJ, Delorenzo MA, Walker-Corkery ES, et al. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: A population-based cohort study. BJU Int. 2006;98:973–978
  57. Potters L, Torre T, Ashley R, et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol. 2000;18:1187–1192
  58. Merrick GS, Butler WM, Wallner KE, et al. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:669–677
  59. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599–603
  60. D'Amico AV. Predicting prostate-specific antigen recurrence established: Now, who will survive?. J Clin Oncol. 2002;20:3188–3190

 Abstract presented at American Society for Therapeutic Radiology and Oncology (ASTRO), 49th Annual Meeting, October 28–November 1 2007, Los Angeles, CA.

 Conflict of interest: none.

PII: S0360-3016(07)04750-5

doi: 10.1016/j.ijrobp.2007.11.073

International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 5 , Pages 1302-1308 , 1 August 2008

Article Tools

* Image Usage & Resolution